Search Results for: 120

— Second Phase 2 Eight Week Extension Study Results Expected in 1Q2016 — — Planning Underway for Initiation of SYN-010 Phase 3 Clinical Trial During 2016 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 8, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), […]

Collaboration Targets Delivery of an Essential Enzyme via ActoBiotics™ Platform without Adverse Impact on Gut Microbiome GERMANTOWN, Md. and ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ — Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases,

— Conference Call Scheduled for Monday, August 10, 2015 at 8:30 a.m. EDT — ROCKVILLE, Md., July 29, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and six months ended June

— Progress Cited On Three Infectious Disease Programs, Including Two Programs in Collaboration with Intrexon Corporation; C. difficile Prophylactic is Lead Anti-Infective Candidate — ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for

— Collaboration Harnesses Monoclonal Antibodies to Address Unmet Medical Needs — — Joint Conference Call Scheduled for Today, Wednesday, August 8, 2012 at 5:00pm(ET)/2:00pm(PT) — ROCKVILLE, Md. and SAN FRANCISCO, Aug. 8, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs, and Intrexon Corporation

ANN ARBOR, Mich., March 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc.  (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics’ proprietary oral formulation of estriol (Trimesta™)